Xcelience Reduces Time to Phase I Studies by 17 Weeks Using API into Capsule Services

Celebrates 100th Xcelodose GMP Batch
TAMPA, Fla.--(Business Wire)--
Xcelience, a leader in early drug development services, has developed a faster,
more cost effective path to Phase I studies using Xcelodose 600 and 600 S
precision powder micro-dosing systems (Xcelodose is a registered trademark of
Capsugel BVBA). API into Capsule projects are on average completed 45 percent
faster than traditional formulation efforts, and in some specific cases we have
saved our clients as much as 17 weeks.

"Today`s molecule is under pressure," says Derek Hennecke, CEO and President.
"We need to work smarter with clients to make the best choices, often with
limited material. One of the best decisions we made was to put our money on
Xcelodose. We were the first CRO in North America to do so, we`ve built up
industry leading expertise, and this month we are proud to announce our 100th
GMP batch."

"Our defined API into Capsule program is a true differentiator, but not the only
one," adds V.P. Randall H. Guthrie. "Xcelience combines decades of drug
development experience, state-of-the-art equipment, a strong audit history, and
sound financial management to deliver solutions that enable our clients to rely
on us to accelerate drug development programs and meet critical milestones."

Xcelience is also announcing a strategic expansion focused on areas of proven
strength: low weight fills and potent compounds for API into capsule, continued
expansion and growth of its formulation development team, implementation of UPLC
analytical capability, investment in x-ray diffraction for preformulation
activities, and blister packaging in support of client`s clinical supply needs.
Development of the purpose-built Grace Street expansion continues as planned.

Xcelience LLC, is a contract research organization which has been providing
formulation development, preformulation, analytical, and clinical trial
manufacturing since 1997. The company has a solid reputation for accelerating
early development activities to speed potential drugs to clinical trials while
applying stage-specific scientific knowledge and experience. Xcelience's unique
corporate structure creates project teams that work intensively with each
client, bringing an extension of their own organization into the Xcelience lab.

About Xcelience: Keep on top of new developments in Xcelience and throughout the
drug development industry by following us on Twitter
www.twitter.com/Xcelience.For more detailed information about Xcelience, visit
www.xcelience.com.

Xcelience
Kim Black-Washington, 206/525-5852

Copyright Business Wire 2009